EyePoint Pharmaceuticals (EYPT) AI Stock Analysis

• Market Cap: $798.87M
• Dividend Yield: N/A
• Average Volume (3M): 649.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.25
• Revenue Growth: 2.99%
• EPS Growth: -49.11%
• Country: US
• Employees: 165
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 68,927,420
• 10 Day Avg. Volume: 759,872
• 30 Day Avg. Volume: 649,643
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 7.57
• Enterprise Value/Gross Profit: 8.11
• Enterprise Value/Ebitda: -2.85
• 1Y Price Target: $32.13
• Price Target Upside: 177.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 55 Neutral
• Price Target: $11.50 ▼(-0.78% Downside)

EyePoint Pharmaceuticals' stock score is primarily influenced by its financial challenges, despite strong technical indicators and positive earnings call sentiment. The company's valuation remains a concern due to negative earnings, but its strategic progress in clinical trials and solid cash position offer potential for future growth.

Positive Factors

Clinical Trials

The rapid pace of enrollment completion for both LUGANO and LUCIA signifies enthusiasm among the wet AMD community for a treatment option with 6-month redosing.

Market Position

EYPT finds itself in the pole position with respect to when the first TKI-based product for wAMD might get approved.

Regulatory Progress

A positive FDA end-of-Phase 2 meeting for DURAVYU in diabetic macular edema suggests favorable progress towards a pivotal Phase 3 program.

Negative Factors

Market Risks

Risks include, but are not limited to: failure of DURAVYU in clinical trials, failure to obtain regulatory approval, failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.

Therapy Limitations

Declining rescue-free rates could dent the value proposition of a one-and-done therapy, as patients would anyway need to come in regularly for monitoring, perhaps more frequently with passing time.

EyePoint Pharmaceuticals Business Overview & Revenue Model

Company Description

EyePoint Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in sustained-release drug delivery systems to treat chronic ocular conditions, particularly in the areas of retinal diseases, glaucoma, and ocular inflammation. EyePoint's core products include Yutiq, an implant for the treatment of non-infectious uveitis, and Dextenza, a dissolvable insert for the treatment of post-surgical pain and inflammation.

How the Company Makes Money

EyePoint Pharmaceuticals generates revenue primarily through the sale of its FDA-approved products Yutiq and Dextenza. The company benefits from a direct sales force that markets these products to healthcare providers, contributing to its revenue streams. Additionally, EyePoint may engage in partnerships or collaborations with other pharmaceutical companies to expand its product offerings and reach new markets, which can also enhance its earnings potential. Furthermore, the company may explore licensing agreements for its proprietary drug delivery technologies, providing another avenue for revenue generation.

EyePoint Pharmaceuticals Financial Statement Overview

Summary

EyePoint Pharmaceuticals shows revenue growth but struggles with profitability and cash flow management. The balance sheet is strong with low leverage, yet persistent negative returns and cash flow challenges pose risks that need addressing for sustainable financial health.

Income Statement

EyePoint Pharmaceuticals shows a mixed performance. Revenue grew from 2024 to TTM (Trailing-Twelve-Months) by 29.5%, indicating a positive growth trajectory. However, profitability remains a concern with significant negative net profit margins of -261.8% in TTM, alongside negative EBIT and EBITDA margins. This suggests challenges in controlling costs and generating profits despite increasing revenues.

Balance Sheet

The company maintains a strong equity position, with a debt-to-equity ratio of only 0.08 in the TTM (Trailing-Twelve-Months). The equity ratio stands at 82.3%, indicating a solid balance sheet with low leverage. However, the return on equity is negative, reflecting ongoing profitability challenges that may affect future financial stability.

Cash Flow

EyePoint Pharmaceuticals faces significant cash flow issues. The free cash flow is negative, and the operating cash flow to net income ratio is unfavorable, indicating that the company is using more cash in operations than it generates. The free cash flow to net income ratio is also negative, highlighting a need for improved cash management and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.04M	43.27M	46.02M	41.40M	36.94M	34.44M
Gross Profit	52.28M	39.56M	41.39M	33.08M	28.76M	28.61M
EBITDA	-148.59M	-129.23M	-69.00M	-96.62M	-50.15M	-35.49M
Net Income	-146.78M	-130.87M	-70.80M	-124.51M	-63.91M	-52.65M
Balance Sheet
Total Assets	362.56M	418.46M	355.18M	180.36M	263.37M	91.72M
Cash, Cash Equivalents and Short-Term Investments	318.19M	370.91M	331.05M	144.56M	211.56M	44.91M
Total Debt	24.08M	21.86M	4.91M	45.77M	38.42M	40.31M
Total Liabilities	64.17M	81.96M	88.86M	83.99M	78.99M	73.18M
Stockholders Equity	298.40M	336.50M	266.32M	96.37M	184.38M	18.54M
Cash Flow
Free Cash Flow	-151.31M	-130.28M	-1.61M	-67.16M	-50.25M	-14.80M
Operating Cash Flow	-148.18M	-126.23M	1.88M	-65.00M	-50.10M	-14.44M
Investing Cash Flow	-200.64M	-219.35M	-3.31M	-17.27M	-33.12M	-362.00K
Financing Cash Flow	162.96M	164.02M	187.07M	-690.00K	216.90M	37.49M

EyePoint Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Positive. The current price of 11.59 is above the 20-day moving average (MA) of 10.70, above the 50-day MA of 10.19, and above the 200-day MA of 8.01, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 62.82 is Neutral, neither overbought nor oversold. The STOCH value of 84.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EYPT.

EyePoint Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	68 Neutral	$1.03B	22.33	18.17%	―	1218.82%	―
PHAR	67 Neutral	$934.06M	―	-3.40%	―	22.68%	42.45%
EYPT	55 Neutral	$798.87M	―	-73.95%	―	2.99%	-49.11%
URGN	54 Neutral	$855.89M	―	-452.20%	―	10.85%	-1.41%
Sector *	51 Neutral	$7.78B	-0.06	-40.08%	2.29%	21.32%	-1.82%
TNGX	47 Neutral	$767.70M	―	-76.09%	―	-42.84%	-17.32%
MGTX	41 Neutral	$609.79M	―	-379.53%	―	366.84%	-35.87%

EyePoint Pharmaceuticals Corporate Events

EyePoint Completes Enrollment for Phase 3 Trials

On July 29, 2025, EyePoint Pharmaceuticals announced the completion of enrollment for its Phase 3 pivotal trials, LUGANO and LUCIA, evaluating DURAVYU for wet AMD. The trials enrolled over 800 patients, marking one of the fastest enrollments for such programs. Interim safety data confirmed DURAVYU’s favorable safety profile, with no serious adverse events related to the drug. The trials are designed to support regulatory approval and aim to reduce treatment burden with a 6-month redosing schedule, potentially shifting the treatment paradigm for wet AMD.

EyePoint Pharmaceuticals Approves Share Increase at Annual Meeting

On June 18, 2025, EyePoint Pharmaceuticals held its Annual Meeting of Stockholders via webcast, where stockholders approved an amendment to increase the number of shares in the 2023 Long-Term Incentive Plan by 2,900,000 shares. Additionally, the meeting included the election of directors, approval of executive compensation, and ratification of Deloitte & Touche LLP as the independent auditor, reflecting strong shareholder engagement and strategic alignment with the company’s growth objectives.

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial

On May 27, 2025, EyePoint Pharmaceuticals announced the completion of patient enrollment in the Phase 3 LUGANO clinical trial for DURAVYU, a treatment for wet age-related macular degeneration (wet AMD). This milestone was achieved with over 400 patients enrolled in seven months, marking one of the fastest enrollments for a Phase 3 trial in wet AMD. The trial’s rapid progress reflects strong interest from both patients and physicians, highlighting the commercial potential of DURAVYU. The LUGANO trial, along with the ongoing LUCIA trial, aims to assess the efficacy and safety of DURAVYU, with topline data expected in mid-2026. The trials are designed to evaluate the potential of DURAVYU to transform treatment paradigms for wet AMD, offering a sustained-release option that could reduce treatment burdens and improve patient compliance.